alpelisib 125 MG Oral Tablet [Vijoice]

RxCUI: 2598463
RxNorm name: alpelisib 125 MG Oral Tablet [Vijoice]
Display name: alpelisib 125 MG Oral Tablet [Vijoice]
Full name: alpelisib 125 MG Oral Tablet [Vijoice]
Term type: SBD
Status: DailyMed mapping
Updated: 2026-06-04 23:39:01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
VIJOICE	ALPELISIB	Novartis Pharmaceuticals Corporation	638069a4-aee0-46c9-9e21-54ad449c163c	2025-11-04	Warnings, Adverse reactions	Exact identifier rxcui: 2598463

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
638069a4-aee0-46c9-9e21-54ad449c163c	alpelisib 125 MG Oral Tablet [Vijoice]	SBD	10	These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019	20251104
638069a4-aee0-46c9-9e21-54ad449c163c	Vijoice 125 MG Oral Tablet	SY	10	These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019	20251104
638069a4-aee0-46c9-9e21-54ad449c163c	Vijoice 125 MG Oral Tablet	PSN	10	These highlights do not include all the information needed to use VIJOICE safely and effectively. See full prescribing information for VIJOICE. VIJOICE ® (alpelisib) tablets, for oral use VIJOICE ® (alpelisib) oral granules Initial U.S. Approval: 2019	20251104